LIPOCINE INC.

What LIPOCINE INC. does

Lipocine Inc. is a clinical-stage specialty pharmaceutical company headquartered in Salt Lake City, Utah, founded in 1997 and publicly traded on NASDAQ under ticker LPCN following a reverse merger in July 2013. The company focuses on developing and commercializing differentiated pharmaceutical products using its proprietary Lip'ral oral drug delivery technology platform, which is designed to improve the bioavailability of poorly water-soluble active ingredients. Headcount is reported in the 11-50 range and market capitalization sits at approximately $20.3M, consistent with a small-cap specialty pharma.

The company's only commercial product is TLANDO, an FDA-approved oral testosterone replacement therapy indicated for hypogonadism in adult males. Its R&D pipeline is broad for its size, spanning central nervous system indications (LPCN 1154/BRLIZIO for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2202 for treatment-resistant depression), neurology (LPCN 2101 for epilepsy, LPCN 2203 for essential tremor), women's health (LPCN 1107 for preterm birth), hepatology (LPCN 1148 for liver cirrhosis), and metabolic disease (LPCN 2401 for obesity as an adjunct to GLP-1 therapy). Lead candidates are progressed via the FDA's 505(b)(2) NDA pathway, leveraging reformulations of approved compounds to shorten clinical timelines.

Lipocine operates a licensing-driven commercial model rather than a direct sales force. Revenue is earned primarily as royalties and milestones from regional partners commercializing TLANDO—Verity Pharma in the U.S., SPC Korea in South Korea, Pharmalink in the GCC, and Aché in Brazil—with pipeline assets also positioned for potential out-licensing. The company's cash position was approximately $24.7M as of March 2026 against a FY2025 net loss of $9.6M and revenue of roughly $2.0M, materially below FY2024 revenue of approximately $11.2M. The April 2026 Phase 3 failure of LPCN 1154 represents the most significant recent strategic event.

Name

LIPOCINE INC.

Legal name

Lipocine Inc.

Website

https://lipocine.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Lipocine Inc. is a specialty pharmaceutical company that develops and commercializes oral drug delivery products, including the FDA-approved testosterone therapy TLANDO and a pipeline across CNS, metabolic, and women's health indications, monetized via regional out-licensing partnerships.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Obesity Medicine & Weight Management (HLAKADAL)

Keywords

• Specialty pharmaceutical products
• Oral drug delivery
• Testosterone replacement therapy
• Neuroactive steroid formulations
• Postpartum depression treatment

Headquarters

HQ city

Salt Lake City

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. License Revenue: Upfront and milestone payments from exclusive license agreements with regional partners for commercialization of TLANDO. License revenue was $1.5 million in 2025 from Verity and Aché agreements. Potential milestone payments of up to $259 million tied to sales and development achievements across all TLANDO partnerships.
2. Royalty Revenue: Ongoing royalty payments from TLANDO sales under license agreements with Verity Pharma (USA and Canada), SPC (South Korea), Pharmalink (GCC), and Aché (Brazil). Royalty revenue was $476,677 in 2025 and $119,000 in Q1 2026.
3. At-the-Market (ATM) Equity Offering: The company sold shares of common stock through an ATM offering under a sales agreement with A.G.P./Alliance Global Partners, entered into in April 2024. This resulted in increased cash position from $14.9 million at year-end 2025 to $24.7 million as of March 2026.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Lipocine is a specialty biopharmaceutical company that develops and commercializes pharmaceutical products using a proprietary oral drug delivery technology platform. Its FDA-approved commercial product TLANDO is an oral testosterone undecanoate therapy for adult male hypogonadism, out-licensed to regional pharmaceutical partners across the US/Canada, South Korea, GCC, and Brazil. Its development pipeline includes oral brexanolone (LPCN 1154/BRLIZIO) for postpartum depression and additional oral neuroactive steroid and anabolic candidates targeting major depressive disorder, epilepsy, essential tremor, obesity, liver cirrhosis, and preterm birth prevention.

Product overview

Lipocine is a biopharmaceutical company with a pipeline of drug candidates targeting large addressable markets with significant unmet medical needs. The company's commercial product is TLANDO®, an FDA-approved oral testosterone replacement therapy. Its development pipeline includes LPCN 1154 (BRLIZIO™) for postpartum depression, LPCN 2201 for major depressive disorder, LPCN 2202 for treatment resistant depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor, LPCN 2401 for obesity management, LPCN 1148 for liver cirrhosis, and LPCN 1107 for prevention of preterm birth. The company leverages a proprietary technology platform to enable effective oral delivery of therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• TLANDO: FDA-approved oral testosterone replacement therapy for adult males with hypogonadism
• BRLIZIO

Products and services

• TLANDO FDA-approved novel oral prodrug of testosterone containing testosterone undecanoate for conditions associated with deficiency of endogenous testosterone (hypogonadism) in adult males, offering the simplicity and convenience of oral dosing for testosterone replacement therapy.
• LPCN 1154 (BRLIZIO) Oral formulation of brexanolone (allopregnanolone) under development for rapid relief treatment of postpartum depression, designed to provide bioequivalent systemic exposure to intravenous brexanolone via convenient at-home regimen over 48 hours without need for medical monitoring.
• LPCN 2201 Unique oral brexanolone formulation being developed as a novel, rapid relief oral treatment option for Major Depressive Disorder (MDD), chemically identical to endogenous human hormone allopregnanolone, a positive allosteric modulator of GABA-A receptor.
• LPCN 2101 Neuroactive steroid GABA positive allosteric modulator being developed for epilepsy treatment, including drug resistant epilepsy (DRE) and women with epilepsy (WWE).
• LPCN 2203 Drug candidate targeted for management of essential tremor.
• LPCN 1148 Drug candidate targeted for management of symptoms associated with liver cirrhosis.
• LPCN 2401 Once daily oral formulation comprising proprietary anabolic androgen receptor agonist expected to serve as adjunct to GLP-1 receptor agonist chronic weight management therapies and/or as monotherapy post cessation of GLP-1 receptor agonist weight management therapies with demonstrated benefits to liver.
• LPCN 1107 Drug candidate for prevention of recurrent pre-term birth.
• LPCN 2202 Drug candidate being developed for treatment resistant depression.

Quantifiable outcome

• 100% of Phase 3 trial participants completed the dosing period with no treatment-related serious adverse events.
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Aché Laboratórios Farmacêuticos S.A.coreChannel Partner/ Reseller/ Distributor · 1 January 2025License and supply agreement with Aché, a Brazilian pharmaceutical company, for development and commercialization of TLANDO in Brazil. Signed in 2025, this partnership extends TLANDO's commercial reach to South America.
• Verity PharmacoreChannel Partner/ Reseller/ Distributor · 1 January 2024Exclusive License Agreement with Verity Pharma for commercialization of TLANDO (oral testosterone replacement therapy) in the United States and Canada. Verity Pharma has rights to market TLANDO if approved in these territories. This is a flagship partnership representing the primary commercialization pathway for Lipocine's only approved product.
• SPC Korea LimitedcoreChannel Partner/ Reseller/ Distributor · 1 January 2024Distribution and license agreement with SPC Korea Limited for the development and commercialization of TLANDO for testosterone replacement therapy in South Korea. SPC holds rights to commercialize the product in South Korea.
• PharmalinkcoreChannel Partner/ Reseller/ Distributor · 1 January 2024Exclusive supply and distribution agreement with Pharmalink to commercialize TLANDO in Gulf Cooperation Council (GCC) countries including Saudi Arabia, Kuwait, United Arab Emirates, Qatar, Bahrain, and Oman. The agreement covers the full commercialization rights for the GCC market.

Scale indicators8 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Biogen: Acquired Sage Therapeutics in 2024 and now controls the Zulresso franchise; Biogen's neurology/CNS portfolio and infrastructure overlap with Lipocine's CNS pipeline in depression and epilepsy.
• Karuna Therapeutics (Bristol Myers Squibb): Karuna developed Cobenfy for schizophrenia and was acquired by BMS in 2024; represents a recent precedent for CNS-focused biopharmas being acquired, with overlapping CNS/depression focus relative to Lipocine's pipeline.
• Halozyme Therapeutics: Drug delivery platform company (acquired Antares Pharma) that has commercialized subcutaneous and specialty delivery technologies; comparable to Lipocine's proprietary oral drug delivery platform in business model.

Direct peers

• Marinus Pharmaceuticals: Develops ganaxolone (Ztalmy), a neuroactive steroid GABA-A receptor positive allosteric modulator for CDKL5 deficiency disorder and seizure disorders; directly comparable mechanism of action to Lipocine's LPCN 2101 (epilepsy) and LPCN 1154 (PPD).
• Madrigal Pharmaceuticals: Developer of Rezdiffra (resmetirom) for MASH/NASH liver disease; directly comparable to Lipocine's LPCN 1148 candidate for liver cirrhosis in metabolic liver disease.
• Axsome Therapeutics: Commercial CNS-focused biopharma with FDA-approved Auvelity for major depressive disorder; overlaps with Lipocine's LPCN 2201/2202 pipeline targeting MDD and treatment-resistant depression.
• Clarus Therapeutics: Markets Jatenzo, an oral testosterone undecanoate product for hypogonadism, directly competing with Lipocine's TLANDO in the same approved indication and route of administration.
• TherapeuticsMD: Women's health-focused pharmaceutical company commercializing hormone and reproductive health products; comparable focus on women's health indications overlapping with Lipocine's maternal health pipeline (PPD, preterm birth).
• Sage Therapeutics: Developer of Zulresso (IV brexanolone), the only FDA-approved treatment specifically for postpartum depression and the originator of the neuroactive steroid approach that Lipocine's LPCN 1154 seeks to replicate in oral form.

Emerging players

• Acadia Pharmaceuticals: CNS-focused biopharma with Nuplazid (Parkinson's psychosis) and pipeline in CNS indications including rare neurological disorders; comparable specialty-neurology commercial and development profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/lipocine-inc-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LIPOCINE INC.